Direct answer
Clinical AI Report · October 7, 2026
Key takeaways
- Tempus is a precision oncology platform for cancer centers and oncology practices, pairing tumor and liquid biopsy genomic profiling with clinical trial matching expanded by its 2025 Deep 6 AI acquisition.
- Tempus is priced for institutions, not individual oncologists, and earns revenue from genomic testing, platform subscriptions and data licensing to pharmaceutical companies, which raises some conflict-of-interest questions.
- Tempus connects a patient’s molecular profile, including PD-L1, MSI-H and TMB biomarkers, to real-world outcomes from 30 million+ de-identified patient records (vendor figure) and to matching clinical trials.
- Tempus genomic results take time to return, so it is not real-time decision support, and it offers no drug dosing, differential diagnosis or literature search.
In this review
Tempus at a glance
- Made by
- Tempus AI, Inc., Chicago, Illinois. Founded by Eric Lefkofsky in 2015; listed on NASDAQ (TEM) since 2024. SEC filings
- Price
- Enterprise and institutional pricing; not sold to individual oncologists.
- What it does
- Genomic profiling of tumor and liquid biopsy samples, AI analysis of molecular and clinical data, and clinical trial matching.
- Biomarkers
- PD-L1, MSI-H, TMB and gene fusions, with transcriptomic and proteomic analysis.
- Data library
- 30 million+ de-identified clinical and molecular patient records (vendor figure). Tempus
- Trial matching
- Expanded by the 2025 acquisition of Deep 6 AI, which added 750+ provider sites (vendor figure).
- Revenue
- Genomic testing, data licensing to pharmaceutical companies and enterprise platform subscriptions.
- Speed
- Genomic results take time to return, so it is not real-time decision support.
- Not included
- Drug dosing, differential diagnosis and literature search.
Who Tempus is for
A good fit for
- Cancer centers that want molecular profiles linked to real-world outcomes and open trials
- Practices treating solid tumors with actionable molecular targets
- Programs trying to enroll more patients in clinical trials
Look elsewhere if
- You are an individual oncologist without institutional access
- You need answers at the point of care; genomic results take time
- You need drug dosing, differential diagnosis or literature search
What is Tempus?
Tempus is a precision oncology platform for cancer centers and oncology practices. It sequences tumor and liquid biopsy samples to find actionable mutations, biomarkers and molecular subtypes, then uses AI to connect a patient’s molecular profile to real-world outcomes from similar patients, published evidence and available clinical trials, drawing on 30 million+ de-identified patient records (vendor figure).
That AI layer is what separates Tempus from a laboratory-only genomic service. Tempus partners with academic medical centers and community oncology practices and offers EHR integration for oncology workflows.
What does Tempus genomic testing look for?
Tempus genomic profiling looks for actionable mutations, biomarkers and molecular subtypes that guide treatment selection, including PD-L1, MSI-H, TMB and gene fusions. It sequences tumor and liquid biopsy samples and adds transcriptomic and proteomic analysis, and Tempus lists treatment response prediction and companion diagnostic support among its features.
How does Tempus match patients to clinical trials?
Tempus compares a patient’s molecular and clinical profile with available trials, replacing slow manual screening. Its 2025 acquisition of Deep 6 AI extended matching to 750+ provider sites. Tempus says the combined platform identifies 25% more eligible patients and recruits up to three times faster than traditional methods; those are vendor figures.
According to the National Cancer Institute, only about 5% of adult cancer patients enroll in clinical trials, partly because matching eligible patients to studies is manual and time-consuming.
How much does Tempus cost?
Tempus is priced for institutions, not individual oncologists. Its revenue comes from three sources: genomic testing, enterprise platform subscriptions and data licensing to pharmaceutical companies. Because it is sold as an institutional service rather than a per-clinician subscription, cancer centers should ask how testing, platform access and any data-sharing terms are billed before signing.
Is Tempus a clinical decision support tool?
Tempus is decision support for one part of cancer care: molecularly guided treatment selection and clinical trial access. It is not a general clinical reference. It offers no drug dosing, differential diagnosis or literature search, and because genomic results take time to return, it cannot answer questions in real time at the point of care.
Strengths and limitations
Strengths
- Largest clinical and molecular oncology dataset (30M+ de-identified patient records)
- Comprehensive genomic profiling with actionable mutation identification
- AI-powered clinical trial matching (25% more eligible patients identified)
- Connects molecular profiles to real-world treatment outcomes
- Deep 6 AI acquisition expands trial matching across 750+ provider sites
- Partnerships with major academic medical centers
- Publicly traded (NASDAQ: TEM) with strong institutional backing
Limitations
- Enterprise/institutional pricing — not accessible to individual oncologists
- Genomic results have inherent turnaround time (not real-time decision support)
- Not a general CDS tool — no drug dosing, differential diagnosis, or literature search
- Data licensing to pharmaceutical companies raises some conflict-of-interest questions
- Most impactful for solid tumors with actionable molecular targets
How Tempus compares
Tempus covers molecular profiling and trial matching. The general tools below answer everyday oncology treatment questions at the point of care, which Tempus does not.
| Product | Price | Who can use it | How it differs |
|---|---|---|---|
| Tempus | Price: Institutional pricing | Who can use it: Cancer centers and oncology practices | How it differs: Genomic profiling, 30M+ de-identified records (vendor figure) and trial matching |
| Vera Health | Price: Free for licensed clinicians and trainees | Who can use it: Outside the US except sanctioned countries (vendor) | How it differs: Cited answers from 60M+ papers (vendor figure), with interaction checks for multi-agent regimens |
| OpenEvidence | Price: Free, ad-supported | Who can use it: Verified clinicians; not in the EU, EEA or UK | How it differs: Cited answers, with NCCN among its content partners |
| UpToDate | Price: $579 a year for one US clinician (October 2026) | Who can use it: Paid subscription; plans vary by country | How it differs: 12,000+ expert-written topics with GRADE-graded recommendations |
How Clinical AI Report rates Tempus
81/100
Specialty review (oncology); not part of the overall clinical rankings
Tempus earns a Very Good rating in oncology for its massive genomic dataset and AI-driven clinical trial matching. The platform is the go-to for molecularly guided treatment decisions, though its narrow oncology focus limits general CDS utility.
- Clinical accuracy · 25%88
- Evidence and citations · 20%85
- Product design · 15%82
- EHR integration · 15%86
- Workflow and speed · 15%78
- Value and pricing · 10%55
How this review was researched
- Sources
- 3 sources, listed below, including Tempus’s Form 10-K, its website and National Cancer Institute data on clinical trial enrollment.
- Evidence labels
- Vendor claims are labelled as vendor figures. Independent studies and preprints are named, with their limits.
- What was not tested
- Clinical AI Report did not run its own accuracy test or measure time savings. The score is an editorial judgment against a published rubric, not a clinical benchmark.
- Independence
- Rankings are editorial opinions, not sponsored placements.
Read the scoring methodology, or send a correction.
Tempus FAQ
Is Tempus a public company?
Yes. Tempus AI, Inc. went public on NASDAQ under the ticker TEM in 2024. Eric Lefkofsky founded the company in Chicago in 2015, and it files annual reports, including a Form 10-K, with the US Securities and Exchange Commission.
Which cancers is Tempus most useful for?
Tempus is most useful for solid tumors with actionable molecular targets, where a biomarker such as PD-L1, MSI-H or TMB, or a gene fusion, can change the treatment choice. Its impact is smaller for cancers without actionable molecular targets.
Does Tempus license patient data to drug companies?
Tempus earns part of its revenue from data licensing to pharmaceutical companies and runs pharmaceutical research partnerships; it describes its 30 million+ patient records as de-identified. The data business raises some conflict-of-interest questions, so ask how data from your patients would be used before signing.
Sources (3)
- Tempus AI, Inc. — SEC Filing (Form 10-K) · U.S. Securities and Exchange Commission
- Only 5% of Adult Cancer Patients Enroll in Clinical Trials · National Cancer Institute
- Tempus website · Tempus